Simplifying Synthesis with Radical Cross-Coupling: Prof. Phil S. Baran of Scripps Research Lectures at Porton

Lecture Highlights: Simplifying Synthesis with Radical Cross-Coupling

Professor Baran delivered a lecture titled “Simplifying Synthesis with Radical Cross-Coupling.” Starting from the practical challenges of contemporary drug development, he showed how radical cross-coupling can be applied across different stages of drug R&D, and illustrated these approaches through case studies. Four key takeaways stood out:

• ~Organic synthesis should move beyond traditional polar retrosynthetic logic, with radical pathways significantly reducing redundant synthetic steps.

• ~Sulfonyl hydrazide reagents provide a built-in driving force for the reaction through the release of nitrogen gas, addressing key redox challenges of radical coupling.

• ~Asymmetric radical coupling, long deemed impossible by textbook logic, has been achieved through an in-cage coupling mechanism that fully retains chirality without chiral ligands.

• ~The next transformation of the pharmaceutical industry will be driven by biocatalysis, scalable C-H activation, and integrated AI-robot closed-loop systems.

He encouraged the researchers in attendance to innovate boldly and to pursue unconventional solutions.

In-Depth Exchange: From Technical Q&A to Industry Outlook

In the Q&A session, Porton's R&D and technical teams engaged Professor Baran on frontier advances in synthetic chemistry, innovative route design and practical technical challenges in ongoing projects, and his detailed answers were met with an enthusiastic response.

To close the event, Professor Baran exchanged views with Oliver on industry trends and the application of AI. In his assessment, biocatalysis is the highest-impact near-term technology for the low-cost, large-scale production of small molecules, peptides and oligonucleotides; scalable C-H activation offers an orthogonal synthetic logic that complements both radical cross-coupling and biocatalysis in the disconnection of highly complex molecules; and closed-loop experimental systems combining AI and robotics are expected to enter widespread industrial use within five to ten years, cutting R&D cycle times for reaction optimization and new molecule discovery by an order of magnitude and playing a substantial role in R&D and manufacturing at leading pharmaceutical companies.

The face-to-face exchange of ideas broadened the technical horizons of Porton's researchers and offered fresh inspiration for tackling complex technical challenges and driving R&D innovation.

Harnessing Global Scientific Expertise to Strengthen Porton's R&D Capabilities

Porton keeps a close watch on the frontiers of global pharmaceutical science and continuously strengthens its R&D and technology capabilities. The company recently established a Technology Management Team (TMT) to coordinate technology strategy, integrate expertise from within and beyond the company on a global scale, and accelerate identification of frontier technologies and key‑technology breakthroughs. Professor Baran's visit is a concrete example of how Porton, through the TMT, brings in global scientific expertise and fosters an open academic culture.